We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Biomarin Pharmaceutical (BMRN) Com Stk USD0.001

Sell:$64.26 Buy:$64.28 Change: $0.81 (1.28%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$64.26
Buy:$64.28
Change: $0.81 (1.28%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$64.26
Buy:$64.28
Change: $0.81 (1.28%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Contact details

Address:
105 Digital Drive
NOVATO
94949
United States
Telephone:
+1 (415) 5056700
Website:
https://www.biomarin.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BMRN
ISIN:
US09061G1013
Market cap:
$11.92 billion
Shares in issue:
190.58 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Alexander Hardy
    President, Chief Executive Officer, Director
  • Brian Mueller
    Chief Financial Officer, Executive Vice President - Finance
  • Henry Fuchs
    President - Worldwide Research and Development
  • C. Greg Guyer
    Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
  • G. Eric Davis
    Executive Vice President, Secretary, Chief Legal Officer
  • Greg Friberg
    Executive Vice President, Chief Research & Development Officer
  • Cristin Hubbard
    Executive Vice President, Chief Commercial Officer
  • James Sabry
    Executive Vice President, Chief Business Officer
  • Erin Burkhart
    Group Vice President, Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.